The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections; Hemophilia A
Intervention: Ibuprofen (Drug); Zidovudine (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Pittsburgh
Summary
To determine if platelet dysfunction and/or pharmacologic drug interaction occurs in patients
taking both AZT and ibuprofen, which might account for enhanced bleeding tendency.
Clinical Details
Official title: Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs
Study design: Treatment
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
Patients must have:
- Hemophilia.
- HIV-seropositivity confirmed by Western Blot.
Prior Medication:
Required:
- AZT for study patients.
Allowed:
- Ibuprofen.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Hospitalization for opportunistic infection, bacterial infection or malignancy.
Concurrent Medication:
Excluded:
- AZT (for control group).
- Antibiotics or other medication for opportunistic infection, bacterial infection, or
malignancy.
Patients with the following prior conditions are excluded:
Hospitalization for opportunistic infection, bacterial infection, or malignancy.
Required:
- Ibuprofen.
- AZT 1-2 gm daily (for study patient) or not taking AZT (for control).
Locations and Contacts
Hemophilia Ctr of Western PA / Univ of Pittsburgh, Pittsburgh, Pennsylvania 15219, United States
Additional Information
Related publications: Ragni MV, Miller BJ, Whalen R, Ptachcinski R. Bleeding tendency, platelet function, and pharmacokinetics of ibuprofen and zidovudine in HIV(+) hemophilic men. Am J Hematol. 1992 Jul;40(3):176-82.
Last updated: June 23, 2005
|
